Clinical Trials

Biologic Correlative Study:

A Randomized Multicenter Trial of Neoadjuvant Taxotere and Adriamycin/Cytoxan (AC): A Biologic Correlative Study

Biomarkers (traits of the genes inside cancer cells) may help us predict how well individual breast cancers respond to chemotherapy drugs (Taxotere and Adriamycin/Cytoxan).

Patient Population:
  • Primary breast cancer must be of clinical and/or radiologic size >3 cm and deemed surgically operable.
All patients will receive the following:
  • Taxotere for 4 treatments, then surgery, followed by Adriamycin and Cytoxan (AC) for 4 treatments: or
  • AC for 4 treatments, then surgery, followed by Taxotere for 4 treatments.

Biopsies may be performed prior to beginning chemotherapy and immediately before the second treatment. Tissue will also be obtained at the time of surgery.

For more information or to have a patient screened, contact the Biologic Correlative Study Coordinator at 713-798-1986.